Skip to main content

and
  1. Article

    Open Access

    Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

    No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests bu...

    Nicolette M. Fonseca, Corinne Maurice-Dror, Cameron Herberts in Nature Communications (2024)

  2. No Access

    Article

    Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer

    Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer genoty** and longitudinal disease monitoring1. However, owing to past emphasis on targeted and low-resolution profiling app...

    Cameron Herberts, Matti Annala, Joonatan Sipola, Sarah W. S. Ng, **nyi E. Chen in Nature (2022)